What is the market price of capmatinib in 2025?

Capmatinib (Capmatinib) is a targeted therapy drug for patients with non-small cell lung cancer who carry MET gene exon 14 jumps. The drug has been officially approved for marketing in China in recent years and has been successfully included in the national medical insurance directory. Although it has entered the medical insurance system, due to its relatively short time on the market, hospitals or pharmacies in some areas may not have fully distributed the drug, and patients' actual domestic drug purchasing channels may be subject to certain restrictions. Therefore, some patients will still choose to purchase the drug through overseas channels to ensure continuity and timeliness of medication.

In the overseas market in2025, the original drug capmatinib still maintains a relatively high price level. Taking common specifications as an example, the price of a box of capmatinib original drug (such as 200mg*60tablets) is mostly between RMB 30,000 and 50,000, with slight differences in prices in different countries and supply channels. This is a considerable burden for many ordinary patient families, especially those who require long-term medication, and the financial pressure is even more obvious. Although medical insurance coverage has alleviated the cost problem to a certain extent, some people still tend to look for more affordable alternatives.

In contrast, generic drugs offer more cost-effective options. At present, Laos has launched a generic version of capmatinib, which is produced by local pharmaceutical companies such as Luzues (Luzues). The specifications are basically the same as the original drug, mainly 200mg*60 tablets or similar packaging. The market price of a box is only more than 2,000 yuan, which is an obvious price advantage. More importantly, Laotian generic drugs are usually produced according to the standards of original drugs, and the ingredients and efficacy of the drugs are basically the same, making them one of the important choices for patients with greater economic pressure.

Taken together,the market price of capmatinib in 2025 shows a clear stratification trend: the price of the original drug is high, but it is supported by medical insurance; the price of generic drugs is affordable and suitable for patients who pay for themselves or have no medical insurance coverage. For patients, choosing a suitable drug source requires comprehensive consideration based on their own financial situation, availability of medical resources, and doctor's advice. On the premise of ensuring efficacy, the popularity of generic drugs has also brought hope to more patients.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib